ABBV vs. TAK: AbbVie vs. Takeda Pharmaceutical Stock Comparison

Company Profile

AbbVie (ABBV) and Takeda Pharmaceutical (TAK) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ABBV is classified in Biotechnology while TAK is classified in Pharmaceuticals.

AbbVie (ABBV) trades as ordinary local shares, while Takeda Pharmaceutical (TAK) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Takeda Pharmaceutical (TAK) reports a negative beta of -0.01, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. AbbVie (ABBV) has a non-negative beta of 0.21.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Takeda Pharmaceutical (TAK) earns 0.56% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.

AbbVie (ABBV) at 15.67% retains a top-quartile share of revenue as profit, ahead of Takeda Pharmaceutical (TAK) at 0.87%, which keeps about the industry-typical share.

Both AbbVie (ABBV) at 39.59% and Takeda Pharmaceutical (TAK) at 24.55% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

AbbVie (ABBV) at 8.57% is around its peer norm for revenue growth, while Takeda Pharmaceutical (TAK) at -1.66% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Takeda Pharmaceutical (TAK) at 77.96% sits in the top EPS growth quartile, while AbbVie (ABBV) at -0.84% is closer to the peer norm — faster per-share earnings growth for TAK.

Growth Metrics

Financial Strength

Both AbbVie (ABBV) at 0.87 and Takeda Pharmaceutical (TAK) at 1.15 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Only one side’s leverage can be read here: Takeda Pharmaceutical (TAK) carries debt-to-equity ratio of 0.72 against its industry range, while AbbVie (ABBV) reports no figure this period.

Financial Strength Metrics

Dividends

Both AbbVie (ABBV) at 2.40% and Takeda Pharmaceutical (TAK) at 953.28% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

Both AbbVie (ABBV) at 117.35% and Takeda Pharmaceutical (TAK) at 426.53% report payout ratio above 100%, meaning dividends exceeded current-period earnings on both sides.

Dividend Metrics

Valuation

Both look expensive on trailing earnings: AbbVie (ABBV) at 50.05 sits in the richer P/E ratio quartile, and Takeda Pharmaceutical (TAK) at 300.29 is richer still, above its industry range.

Takeda Pharmaceutical (TAK) at 0.01 sits in the cheaper P/S ratio quartile while AbbVie (ABBV) at 7.80 prices around its industry’s middle — TAK costs less per dollar of sales, though read it alongside growth and margins.

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Takeda Pharmaceutical (TAK) reports 1.43, ranking against industry peers normally.

Valuation Metrics